Most material SEC filings — July 30, 2026

Eurus Aerospace Token I LLC (a Forum Markets entity per Section 14 notice address) agreed to purchase one CFM International CFM56-7B aircraft engine from Aero Engine Solutions, Inc. for $11,650,000. The agreement, dated July 27, 2026, provides for closing by July 30, 2026, with the engine sold as-is, where-is, with all faults. Forum Markets will include Seller as additional insured on aviation liability policies up to $600M combined single limit for two years post-closing.

ICE agreed to acquire MarketAxess Holdings Inc. for $167.00 per share in an all-cash transaction, valuing the company at approximately $5.87 billion in equity consideration (based on 35.19M shares outstanding as of July 27, 2026). The merger agreement was signed July 29, 2026, with ICE using a wholly-owned subsidiary (Igloo Merger Sub II) to merge with MarketAxess, which will become a wholly-owned subsidiary of ICE. The deal requires MarketAxess shareholder approval and regulatory clearances including HSR and FINRA approval.

MarketAxess entered into a definitive merger agreement to be acquired by Intercontinental Exchange, Inc. (ICE). The filing does not disclose the acquisition price, deal terms, or timing. In 2Q26, MarketAxess reported total revenues of $218.4M (flat YoY), diluted EPS of $1.93 ($1.95 ex-notable items), and suspended guidance, conference calls, and monthly volume releases pending deal completion.

Chief Executive Officer Huang Jack Jiajia (COE) bought 637K shares (~$10.7M) on the open market (1.9% of holdings). Open-market insider purchase — historically a bullish signal.

On May 18, 2026, Quince Therapeutics completed acquisition of Orphai Therapeutics for an undisclosed upfront amount. Quince received $115 million gross upfront proceeds in a private placement from a 13-member investor syndicate led by Balyasny, Affinity, Coastlands, and others. Up to $72 million additional warrant exercise proceeds are available, plus $11 million to former Orphai shareholders. LAM-001 (inhaled rapamycin dry powder) is Quince's lead asset: Phase 2a in PH-ILD/PAH completed (10 patients, 6 completed); Phase 2b ongoing in PH-ILD (75 patients, Q1 2028 data); Phase 2 in BOS ongoing (19 patients, fully enrolled, Q1 2027 data); Phase 2 SAPH planned (late 2026, Q4 2028 data). Orphan drug designations granted for BOS, PAH, LAM, sarcoidosis (US) and BOS, LAM (EU).

Darling Ingredients reported Q2 2026 net income of $387.3M ($2.41/share diluted) vs. $12.7M ($0.08/share) in Q2 2025. Combined Adjusted EBITDA surged to $741.7M from $249.5M YoY, driven by Diamond Green Diesel (DGD, 50% owned JV) which generated $389.2M of Darling's share vs. $42.6M prior year. DGD sold 348.8M gallons at $2.23/gallon EBITDA (vs. $0.34 in Q2 2025) due to finalized RVO mandates and improved renewable diesel margins. Company received $280M cash from DGD ($211M dividends, $69M tax credits), reduced net debt by $223M, repurchased $73M stock, and closed Brazil rendering acquisition (~$122M) and grease trap business sale (~$90M).

Mangoceuticals (MGRX, ~$14.7M market cap) is combining with Nuclea Energy, a British Columbia nuclear technology company developing the Morpheus Microreactor. Nuclea shareholders will receive ~96% equity of Mango on a fully diluted basis post-closing via exchangeable shares. A $15M minimum PIPE financing is a closing condition. CEO Jacob D. Cohen will transition to President with $1.5M severance, 2M bonus shares, and a $10M Mango & Peaches warrant. Closing expected before August 21, 2026; Mango stockholder and Nasdaq approvals required post-closing.

Expand Energy Corporation (Buyer) agreed to acquire Twin Eagle Holdings N.A., LLC and its subsidiaries (Acquired Entities) via merger for a Base Purchase Price of $1,250,000,000, with a $62.5M deposit and up to $20M–10% post-closing escrow. Purchase price subject to working capital and debt adjustments. Deal dated July 24, 2026; closing contingent on HSR clearance and regulatory approvals. Buyer will assume ~$500M indebtedness and pay transaction expenses (~50% Buyer/Seller split).

Republic Airways reported Q2 2026 revenues of $571.1M (up 40.8% YoY) and net income of $31.2M ($0.68 per diluted share). The company raised full-year 2026 guidance: revenues from ~$2.0B to ~$2.1B, adjusted EBITDAR from >$380M to $395–$405M, and block hour production from ≥865k to ≥880k hours. Matt Koscal became President & CEO effective June 15, 2026. The Mesa Airlines merger (closed Nov 25, 2025) added 60 E175 aircraft for United Airlines; integration expected to take 18–24 more months.

On June 16, 2026, YUM Brands entered definitive agreements to divest Pizza Hut: LongRange Capital (private equity) will acquire Pizza Hut excluding Mainland China; Yum China will acquire Pizza Hut in Mainland China and remain master franchisee for KFC and Taco Bell there. Pizza Hut Q2 2026 operating profit declined 12% YoY to $70M (27.6% margin vs. 33.5% prior year). The divestiture is structured to maximize shareholder value while tailoring Pizza Hut to distinct markets. Expected close Q3 2026 with $359M net deferred tax benefit recognized upon signing definitive agreements.

Martin Marietta entered a definitive agreement on June 27, 2026, to acquire Lhoist North America (LNA) for approximately $13.5 billion in cash and stock, expected to close H2 2026. The deal combines LNA's 20 lime/mineral quarries and 45 distribution terminals with MLM's aggregates platform. MLM also raised full-year 2026 revenue guidance to $7.2B–$7.4B (from prior range) while reaffirming Adjusted EBITDA guidance of $2.36B–$2.5B; separately identified $350M in annualized cash flow improvements from operational efficiencies and identified $200M+ cash benefits year-to-date.

Pagaya reported Q2 2026 GAAP net income of $45M (up $29M YoY), total revenue of $387M (+19% YoY), network volume of $3.5B (+33% YoY), and adjusted EBITDA of $124M (+43% YoY). The company raised full-year 2026 net income guidance to $155–$180M (from prior implied ~$131M), implying a 4Q26 exit rate exceeding $200M annualized. Auto lending drove 75% of YoY volume growth; company maintained ~1% conversion rate and flat core opex while deploying $3.7B in ABS funding across 6 transactions.

EyePoint announced completion of enrollment in COMO and CAPRI, two global Phase 3 trials of DURAVYU for diabetic macular edema (DME), with over 480 patients enrolled across both trials in five months—ahead of schedule. The trials compare DURAVYU 2.7mg (dosed every six months) to on-label 2mg aflibercept control with non-inferiority primary endpoint on visual acuity at weeks 52/56. Topline data for both DME trials are anticipated in Q4 2027; wet AMD Phase 3 data (LUGANO and LUCIA, with 900+ patients) expected to report beginning August 2026.

Replimune presented to FDA advisory committee on July 30, 2026, seeking accelerated approval of vusolimogene oderparepvec-wtpg (TUDRIQEV/RP1) combined with nivolumab for unresectable advanced cutaneous melanoma in patients with disease progression on anti-PD-1 therapy. The IGNYTE Phase 2 trial (N=140) showed 33.6% ORR (95% CI: 25.8-42%) with median duration of response of 24.8 months; median OS 32.9 months (3-year OS rate 47.8%). Safety profile was manageable with mainly Grade 1-2 adverse events and no treatment-related Grade 5 deaths in the melanoma cohort. FDA clinical reviewers recommended approval on July 15, 2025, noting the 33.6% ORR was substantially higher than the 5-7% expected with further anti-PD-1 monotherapy, and superior to lifileucel (AMTAGVI, 31.5% ORR with 7.5% treatment-related mortality).

First Carolina Financial Services completed its IPO on June 22, 2026, raising net proceeds of $69.3 million after underwriting costs by selling 5,500,000 shares at $12.50/share, plus 825,000 additional shares via underwriter option. Q2 2026 net income was $5.1 million ($0.20 diluted EPS), up 11% YoY; the company achieved a 3.23% net interest margin (18 bps expansion YoY), generated $58.1M loan growth (8.9% annualized), and reduced CDs by 53.5% YoY. Tangible book value per share was $11.66; the company serves 3.4B in assets with operations across Carolinas, Virginia, and Georgia.

Solstice reported Q2 2026 net sales of $1,148M (up 11% YoY) and net income of $119M (up 23% YoY), with adjusted EBITDA of $290M and adjusted diluted EPS of $0.88. The company raised full-year 2026 guidance: net sales to $4,125–$4,185M (from $3,900–$4,100M), adjusted EBITDA to $1,035–$1,055M (from $975–$1,025M), and adjusted diluted EPS to $2.75–$2.95 (from $2.45–$2.75). On July 6, 2026, Solstice announced a definitive agreement to acquire Element Solutions in a cash-and-stock transaction, expected to close in H1 2027, subject to shareholder and regulatory approval.

CRH agreed to acquire Arcosa Inc. for $8.5 billion ($150/share, all-cash) on June 22, 2026, targeting Q1 2027 close (subject to regulatory approval and stockholder vote). The deal is funded via a $5.8B bridge facility. In Q2 2026, CRH reported total revenues of $10.8B (+6% YoY), net income of $1.5B (+13% YoY), and Adjusted EBITDA of $2.6B (+7% YoY); year-to-date acquisitions totaled $1.4B across 17 deals. CRH reaffirmed full-year 2026 guidance: net income $3.9B–$4.1B, Adjusted EBITDA $8.1B–$8.5B, diluted EPS $5.60–$6.05.

WESCO reported Q2 2026 net sales of $6.665B (+13% YOY, +10% sequentially; organic +12.6%), with adjusted EBITDA of $487M (+24% YOY, 7.3% margin +60bps) and adjusted EPS of $4.57 (+35% YOY). Backlog surged ~60% YOY to record levels, driven by data center sales up ~45% YOY to $1.5B in Q2. The company raised full-year 2026 guidance: reported sales growth 10-12% (from 6-9%), adjusted EBITDA margin 6.9-7.1% (from 6.6-7.0%), adjusted EPS $16.00-$17.50 (from $15.00-$17.00). Newark Engineering acquisition closed July 1, 2026 (~$60M 2025 sales). Net debt improved to 3.0x leverage from 3.4x at year-end 2025.

Agios reported Q2 2026 net product revenues of $44.7M (vs. $12.5M YoY), driven by U.S. AQVESME launch in thalassemia with 442 cumulative prescriptions as of June 30, 2026. FDA granted Priority Review for mitapivat sNDA in sickle cell disease with PDUFA goal date November 1, 2026. Company licensed cevidoplenib from Oscotec for $25.0M upfront (potential $1.0B peak U.S. sales in ITP) and advanced AG-236 into Phase 2/3 for polycythemia vera. Cash position: $964.8M (vs. $1,164.4M Dec 31, 2025); net loss: $100.7M vs. $112.0M YoY.

CSW Industrials reported fiscal Q1 2027 (ended June 30, 2026) revenue of $350.6M (+33% YoY), driven by $73M inorganic growth from five acquisitions completed since May 2025 (including MARS Parts and Aspen Manufacturing) plus 5.3% organic growth. Diluted EPS increased 25% to $3.04; adjusted EPS rose 35% to a record $3.84. Adjusted EBITDA grew 48% to $101.6M (29.0% margin). Net debt stood at $815M with net leverage of 2.37x (within 1-3x target). The company invested $1.0B in acquisitions over the past year while returning capital via share repurchases and maintaining a 30-consecutive-quarter dividend ($0.30/share announced).

Effective October 30, 2026, Michael S. Ettinger (EVP/COO), Mark E. Mlotek (EVP/Chief Strategy Officer), and James Mullins (SVP Global Supply Chain) will transition from executive roles to Senior Advisor positions. The company is restructuring from an Executive Management Committee to a Henry Schein Leadership Team and integrating its global supply chain with distribution operations to accelerate decision-making and simplify the operating model. No severance amounts, equity arrangements, or compensation changes are disclosed in this filing.

Builders FirstSource reported Q2 2026 net sales of $3.862B (down 8.8% YoY) driven by lower housing starts, weak demand across single-family (-8.1%), multi-family (-9.7%), and repair/remodel segments (-1.8%). Net loss was $3.9M (EPS -$0.04) versus $185.0M profit ($1.66 EPS) in Q2 2025. Gross margin contracted 260 bps to 28.1%. The company lowered full-year 2026 guidance to net sales of $14.0B–$14.8B and Adjusted EBITDA of $1.0B–$1.2B, reflecting persistent housing affordability challenges and softer demand.

Steven Madden reported Q2 2026 revenue of $665.9M (up 19.1% YoY) with net income of $27.7M ($0.38 diluted EPS), reversing a $39.5M loss in Q2 2025. The company raised FY2026 revenue guidance to 11-13% growth (from 10-12%) and adjusted diluted EPS to $2.05-$2.15 (from $2.00-$2.10), while reaffirming GAAP EPS guidance at $2.55-$2.65. Ken Pilot, former executive at J.Crew, Gap Inc., and Ralph Lauren, was appointed to the board effective October 1, 2026; the company maintained its $0.21 quarterly dividend.

Leonardo DRS reported Q2 2026 revenue of $913M (up 10% YoY), net earnings of $86M (up 59%), and adjusted EBITDA of $128M (up 33%). The company raised 2026 guidance for adjusted EBITDA to $525–540M (from $515–530M) and adjusted diluted EPS to $1.34–$1.39 (from $1.26–$1.30). Additionally, DRS announced a $450M acquisition of Raft LLC to expand AI, data fusion, and mission software capabilities; funded backlog reached a record $5.1B (up 17% YoY); the company holds $270M cash with no debt outstanding; and declared a $0.09/share dividend payable August 27, 2026.

Jones Lang LaSalle reported Q2 2026 diluted EPS of $4.59 (up 98% USD/100% local currency) on revenue of $6.9B (up 11% USD/10% local currency). Adjusted EBITDA increased 32% to $386.3M; Advisory revenues accelerated 21%. The company completed a $200M accelerated share repurchase program (638,400 shares total) and raised full-year adjusted EPS guidance to 34% growth at midpoint. Operating cash flow improved 47% to $488.1M; net debt declined to $1.19B with 0.7x leverage ratio.

Acadian Asset Management (market cap ~$935M) reported Q2 2026 results with: AUM of $232.7B (up 54% YoY from $151.1B), driven by $4.3B net inflows (9% annualized growth) and $32.7B market appreciation. Management fees reached record $176.5M (up 44% YoY), ENI surged to $47.5M (up 107% YoY), and ENI EPS doubled to $1.33 (up 108% YoY). ENI operating margin expanded 959 basis points to 40.3%. The company repurchased 0.2M shares ($10.6M at $69.92/share) and declared a $0.10/share quarterly dividend.

Saia posted Q2 2026 revenue of $956.5M (up 17.1% YoY) and operating income of $125.2M (up 26.0% YoY), with diluted EPS of $3.51 vs. $2.67 prior year. Operating ratio improved to 86.9% from 87.8%. Cash position strengthened to $84.0M from $18.8M YoY; total debt reduced to $100.1M from $309.1M. LTL tonnage per workday rose 8.4%, shipments per workday 4.4%; pricing (ex-fuel) declined 2.2% per cwt but rose 1.5% per shipment on mix. H1 2026 capex was $158.0M vs. $375.6M prior year; FY 2026 guidance $350-400M.

Willis Towers Watson announced Propel, an AI acceleration plan expected to invest ~$625M in cash through 2028 to generate ~$400M in run-rate savings (1.6x cost-to-achieve ratio), targeting ~30% adjusted operating margin by 2028 (vs. 25.2% in 2025). Q2 2026 showed 5% organic revenue growth ($2.47B), adjusted diluted EPS of $3.35 (+17% YoY), and adjusted operating margin of 19.5% (+100 bps). The company also increased share repurchase authority by $1.5B and repurchased 1.73M shares for $450M in the quarter.

Columbus McKinnon reported Q1 FY27 net sales of $531.5M (up 125% YoY), driven by the Kito Crosby acquisition closed Feb 3, 2026. GAAP net loss was $88.7M ($2.05/share) due to $70.3M in acquisition and integration costs; adjusted EBITDA was $111.5M (21% margin). The company raised full-year FY27 guidance: net sales $2.09–$2.15B (prior $2.05–$2.12B), adjusted EBITDA $405–$420M (prior $390–$410M), adjusted EPS $1.90–$2.10 (prior $1.70–$1.90). Credit Agreement net leverage ratio stood at 4.9x; total liquidity $567.1M.

Xerox reported Q2 2026 revenue of $1.92B (+22.0% YoY, +21.2% constant currency) and adjusted operating income of $203M (+$144M YoY). The company raised full-year 2026 revenue guidance to ~$7.6B and adjusted operating income guidance to $555–$605M (from $450–$500M). Key drivers: Lexmark acquisition (completed July 1, 2025) contributing synergies; a $105M pre-tax IEEPA tariff receivable benefit recognized in Q2, of which $80M was monetized in cash; and debt reduction of $200M. Adjusted operating margin expanded 6.9 percentage points YoY to 10.6%, though on a pro forma basis (including Lexmark) Q2 revenue declined 6.5% due to legacy Xerox revenue headwinds in equipment and post-sale segments.

XPO reported Q2 2026 diluted EPS of $1.36 (vs. $0.89 YoY) and adjusted diluted EPS of $1.70 (vs. $1.05 YoY). Revenue rose 13.2% to $2,355M; operating income +36.9% to $271M. North American LTL segment drove performance with 36% adjusted operating income growth and 300bp margin expansion to 79.9% adjusted operating ratio. European Transportation swung to $6M operating loss (from $11M profit) due to restructuring ($21M costs). Adjusted EBITDA grew 27.6% to $434M. Company generated $308M operating cash flow, repurchased $70M stock, repaid $70M debt.

Granite Construction reported Q2 2026 revenue of $1.46B (up 29% YoY) and raised full-year 2026 revenue guidance by $100M to $5.3–$5.5B. Adjusted net income was $101M ($2.16/share, up from $1.93/share prior year); reported GAAP net loss of $278M reflects a $360M non-operating loss on 3.75% convertible debt settlement. Adjusted EBITDA rose 22% to $186M. CAP increased $250M sequentially to $7.4B. Company completed acquisitions of Warren Paving, Papich Construction, and Kenny Seng Construction ($98M revenue contribution in Q2).

Coastal Financial (market cap ~$1.3B) recorded a net loss of $42.1M in Q2 2026 driven by a single non-public company CCBX partner relationship: $22.8M provision for credit losses and $46.0M valuation adjustment to a credit enhancement asset. Excluding this partner, core CCBX loans grew 46% YoY to $1.70B with improved credit metrics (net charge-offs 8.73%, down 20% YoY; delinquencies 5.48%, down 0.07% YoY). Total loans grew $348.9M (9.0% QoQ) to $4.21B; BaaS program fees grew 10.3% QoQ to $12.0M.

PBF Energy reported Q2 2026 net income of $906.4M ($7.54/share) versus Q2 2025 net loss of $5.2M ($0.05/share). The company received a fifth insurance installment of $250M related to the February 2025 Martinez refinery fire (totaling $1.25B to date against $30M deductible), with the refinery returning to full operations in May 2026. PBF reduced gross debt by >$1B in Q2 through refinancing and facility paydown, lowering net debt to $855M, and declared a $0.275/share dividend.

Life Time reported Q2 2026 revenue of $866.0M (+13.7% YoY), net income of $101.4M (+40.6%), and adjusted EBITDA of $246.5M (+16.8%). The company raised full-year 2026 revenue guidance to $3,350–$3,375M (from $3,320–$3,350M), increased comparable center revenue growth guidance to 7.9–8.3% (from 6.9–7.5%), and tightened new club openings to 14 (from 12–14). Center memberships reached 860,041 (+1.2% YoY); average revenue per membership grew 11.8% to $993. Net debt leverage improved to 1.4x from 1.8x YoY. The company repurchased 2.2M shares for $62.7M at $28.59/share and completed $200M in sale-leaseback transactions in H1.

Madison Air (NYSE: MAIR) completed IPO on April 17, 2026, raising $2.584B net proceeds plus $41.5M cash on hand to repay $2.626B debt, reducing net leverage to 2.8x. Q2 2026 net sales $991.3M (+21% YoY), net income $70.5M (+129%), adjusted EBITDA $265.8M (+18%). Backlog surged to $2.868B (+133% YoY). Company raised FY 2026 net sales guidance to $3.825–$3.925B (from $3.750–$3.850B) and confirmed adjusted EBITDA guidance of $1.020–$1.065B. AprilAire acquisition (May 6, 2025) contributed meaningfully to residential segment growth.

Crocs, Inc. reported Q2 2026 consolidated revenues of $1,179.5M (+2.6% YoY), with the Crocs brand surpassing $1.0B in quarterly revenue for the first time ($1,000.4M, +4.3% YoY). The HEYDUDE brand declined 5.7% to $179.0M. The company raised full-year 2026 guidance to revenue growth of +1% to +2% (from -1% to +1%), and adjusted diluted EPS to $13.70–$14.00 (from $13.20–$13.75). The Board increased share repurchase authorization by $1.5B to ~$2.0B total; in Q2, the company repurchased 2.3M shares for $251M and repaid $31M of debt.

Madrigal reported Q2 2026 Rezdiffra net sales of $364.3 million (71% YoY growth) with 49,000+ patients on therapy as of June 30, 2026. The company strengthened IP with 3 new resmetirom patents (F2-F3 dosing/rosuvastatin combo, F4c cirrhosis treatment, protection through 2042–2045) and initiated Phase 1 dosing of MGL-2086 (oral GLP-1) in June 2026 for combination MASH therapy. Cash position: $838.9 million as of June 30, 2026 (down from $988.6 million at year-end 2025); Q2 net loss was $57.9 million ($1.99/share) vs. $42.3 million prior year, including $25 million one-time business development expenses.

AMC Global Media signed a 5-year, $500M licensing deal with Netflix for co-exclusive global streaming rights to all Walking Dead Universe content (7 series, 371 episodes). Cash payments: ~$25M in 2026, ~$100M annually in 2027–2030, remainder in 2031. AMC expects $200–225M annual revenue recognition in 2026–2027. Company also repaid $80M Term Loan A debt and initiated $30M ASR with Citibank on May 8, 2026.

Terex reported Q2 2026 sales of $2.2B (50.5% reported growth; 8.5% pro forma), adjusted EBITDA of $269M (12.0% margin), and adjusted EPS of $1.37. The company raised full-year 2026 guidance to $7.9–8.2B sales and $960M–$1.0B adjusted EBITDA (12.2% margin midpoint), citing strength in all segments, $6.9B backlog (up 3.9% pro forma YoY), $2.0B bookings (up 25.2% pro forma), and ~$28M in realized synergies from the REV Group acquisition (announced Feb 2, 2026; 11-month impact in 2026 outlook). Free cash flow was $101M; liquidity $1.1B.

Phathom reported Q2 2026 net revenues of $74.3M (88% increase vs Q2 2025; 27% vs Q1 2026), with ~1.7M total VOQUEZNA prescriptions filled. Operating expenses fell 33% YoY to $63.1M; non-GAAP adjusted net loss was $0.1M (vs $56.5M loss in Q2 2025). Company revised full-year 2026 guidance down to $310–325M revenue (from $320–345M) and non-GAAP opex $235–245M (from $235–255M), citing 'more moderate' H2 growth. Cash position $182.5M; company initiated Phase 3 as-needed VOQUEZNA trial for NERD and completed EoE Phase 2 enrollment.

Allegro reported Q1 FY2027 (ended June 26, 2026) net sales of $259.2M, up 27% YoY from $203.4M. GAAP diluted EPS improved to $0.08 from $(0.07) loss YoY; non-GAAP diluted EPS grew to $0.23 from $0.09, a 156% increase. Gross margin expanded to 48.5% GAAP (51.1% non-GAAP) from 44.9% (48.2%) YoY. Data center reached record 17% of sales; automotive sales grew 15% to $165.3M, industrial/other surged 59% to $93.9M. Q2 FY2027 guidance: $265–$275M sales (26% YoY growth midpoint); non-GAAP diluted EPS $0.23–$0.26 (88% YoY growth midpoint).

AMG reported Q2 2026 diluted EPS of $6.95 (economic EPS $8.29, +54% YoY) on net income of $185.9M. Record AUM of $942.4B (+$171B or 22% over 12 months) driven by $35.5B net client cash flows YTD, including record $58B alternative inflows YTD. Company repurchased $375M stock in H1 2026 and divested myCIO advisor team for $14.6M pre-tax gain.

Huntington Ingalls Industries reported Q2 2026 revenues of $3.4B (up 10.9% YoY), net earnings of $208M ($5.27 diluted EPS), and raised full-year shipbuilding revenue guidance from $9.7–9.9B to $10.2–10.4B while raising the low end of shipbuilding operating margin guidance to 6.0–6.5%. Segment operating margin improved 100 bps to 6.6%, and backlog grew to $57.3B following $6.7B in new contract awards. However, free cash flow turned negative: –$150M in Q2 (vs. +$730M in Q2 2025) and –$611M YTD (vs. +$268M in H1 2025), driven by working capital headwinds and inventory buildup.

TriNet reported Q2 2026 GAAP diluted EPS of $1.15 (50% YoY growth) and Adjusted EPS of $1.55 (35% growth). Total revenues declined 5% to $1.178B; Average Worksite Employees fell 11% to 298,000. The company raised full-year 2026 guidance: Adjusted Net Income per share now $4.50–$5.10 (previously implied lower), Adjusted EBITDA margin 8.5–9.0%, total revenues $4.75–4.90B. Adjusted EBITDA margin expanded 240 bps YoY to 10.9%, driven by improved insurance cost ratio (86% vs. 90%) and cost management.

HNI Corporation (market cap ~$1.7B) reported Q2 2026 net sales of $1,472.4M (+121% YoY), driven primarily by the Steelcase acquisition completed in December 2025 ($806.9M in incremental sales). GAAP diluted EPS was $0.70 (-31% YoY) but non-GAAP diluted EPS was $1.27 (+14% YoY), benefiting from tariff refunds, productivity gains, and Steelcase accretion. The company raised full-year 2026 non-GAAP EPS growth guidance from prior expectations to 20-25% growth and expects at least $120M in Steelcase synergies when fully mature, plus ~$30M in legacy workplace network optimization savings through 2028.

APi Group reported Q2 2026 net revenues of $2.254B (+13.3% YoY, +10.1% organic) and adjusted EBITDA of $311M (+14.3% YoY, +10 bps margin expansion to 13.8%). The company raised full-year 2026 guidance: net revenues to $8.875–$9.025B (from $8.660–$8.860B) and adjusted EBITDA to $1.205–$1.245B (from $1.177–$1.237B). Record backlog exceeds $5B; Safety Services grew 8.8% ($1.482B revenues), Specialty Services grew 22.9% ($773M revenues).

LKQ reported Q2 2026 revenue of $3.4B (down 3.0% YoY) with diluted EPS of $0.52 vs. $0.72 prior year. The company cut 2026 full-year guidance: diluted EPS now $1.78–$2.08 (vs. $2.16–$2.46 prior) and adjusted EPS to $2.60–$2.90 (vs. $2.90–$3.20). North America returned to organic growth (first time in 9 quarters at ~40% alternative-parts utilization), but Europe disappointed due to Germany ERP implementation; Specialty faced macro headwinds. A comprehensive strategic review (initiated January 2026, including potential company sale or Specialty segment divestiture) remains active with multiple parties engaged. Total debt is $4.0B (2.8x leverage); the company returned $207M to shareholders in H1 2026 via $53M in buybacks (1.9M shares) and $154M in dividends.

Belden reported Q2 2026 revenues of $750M (up 12% YoY, 8% organic), GAAP EPS of $1.74 (up 14% YoY), and adjusted EPS of $2.34 (up 24% YoY). Record orders reached $836M (up 19% YoY) with book-to-bill of 1.11. The company completed its previously announced acquisition of RUCKUS Networks on July 1, 2026, after quarter-end. Q3 2026 guidance: revenues $950–970M, adjusted EPS $2.15–2.30. No acquisition purchase price disclosed in this filing.

Marcus Corporation reported Q2 fiscal 2026 net earnings of $15.8M ($0.51/share), up 116% from $7.3M ($0.23/share) in Q2 2025. Total revenues reached $231.7M (up 12.5% YoY); operating income jumped to $27.1M (up 108%), and Adjusted EBITDA grew 43% to $46.2M. Marcus Theatres same-store admissions grew 16.6%, outperforming industry by 5.1 points; Marcus Hotels achieved record Q2 revenue ($70.8M, +9.6%) and Adjusted EBITDA ($14.7M, +31.1%) with RevPAR up 13.9%.